GLMD

Galmed Pharmaceuticals Ltd. [GLMD] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

GLMD Stock Summary

Top 10 Correlated ETFs

GLMD


Top 10 Correlated Stocks

GLMD


In the News

09:26 28 Mar 2024 GLMD

Why Is Galmed Pharmaceuticals (GLMD) Stock Moving Today?

Galmed Pharmaceuticals (NASDAQ: GLMD ) stock is on the move Thursday after the company priced a public offering of its shares. Galmed Pharmaceuticals intends to offer up 6,578,947 shares of GLMD stock at a price of $2.28 per share.

08:57 28 Mar 2024 GLMD

Why Is Galmed Pharmaceuticals (GLMD) Stock Up 37% Today?

Galmed Pharmaceuticals (NASDAQ: GLMD ) stock is gaining on Friday after the company announced an investment agreement with OnKai . That agreement has Galmed Pharmaceuticals making a $1.5 million equity investment in OnKai.

01:29 28 Mar 2024 GLMD

Galmed Pharmaceuticals (GLMD) Moves to Buy: Rationale Behind the Upgrade

Galmed Pharmaceuticals (GLMD) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

01:56 28 Mar 2024 GLMD

Galmed Pharmaceuticals Ltd. (GLMD) CEO Allen Baharaff on Q4 2021 Results - Earnings Call Transcript

Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD ) Q4 2021 Earnings Conference Call May 2, 2022 8:30 AM ET Company Participants Allen Baharaff - President and CEO Yohai Stenzler - Chief Accounting Officer Conference Call Participants Steven Seedhouse - Raymond James Kristen Kluska - Cantor Fitzgerald Naz Rahman - Maxim Group Operator Good day and welcome to the Galmed Conference Call to discuss Financial Results for the Fourth Quarter and Year-end 2021.

03:24 28 Mar 2024 GLMD

Galmed Pharmaceuticals Ltd. (GLMD) CEO Allen Baharaff on Q3 2021 Results - Earnings Call Transcript

Galmed Pharmaceuticals Ltd. (GLMD) CEO Allen Baharaff on Q3 2021 Results - Earnings Call Transcript

11:49 28 Mar 2024 GLMD

Galmed's Anti-Inflammatory Compound Shows Encouraging Preclinical Action

Galmed Pharmaceuticals Ltd (NASDAQ: GLMD) has announced the data publication for its preclinical compound, Amilo-5MER, in the Journal of Autoimmunity. Amilo-5MER is a five amino acid in a specific sequence originally isolated from synovial fluid of rheumatoid arthritis patients.

08:00 28 Mar 2024 GLMD

Galmed Pharmaceuticals Announces Publication in "The Journal of Autoimmunity" for its IND ready, Amilo-5MER, a specific anti-inflammatory compound

TEL AVIV, Israel, Aug. 19, 2021 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, metabolic and inflammatory diseases announced today the publication in The Journal of Autoimmunity for its IND ready compound, Amilo-5MER entitled: "MTADV 5-MER peptide suppresses chronic inflammations as well as autoimmune pathologies and unveils a new potential target-Serum Amyloid A.

11:00 28 Mar 2024 GLMD

Galmed Pharmaceuticals Ltd. (GLMD) CEO Allen Baharaff on Q2 2021 Results - Earnings Call Transcript

Galmed Pharmaceuticals Ltd. (GLMD) CEO Allen Baharaff on Q2 2021 Results - Earnings Call Transcript

08:29 28 Mar 2024 GLMD

GLMD Stock Increases Over 4% Pre-Market: Why It Happened

The stock price of Galmed Pharmaceuticals Ltd (NASDAQ: GLMD) increased by over 4% pre-market. This is why it happened.

07:30 28 Mar 2024 GLMD

FDA Agrees with Galmed's Plan to use Aramchol Meglumine in the Randomized Double-Blind Placebo-Controlled Part of the Phase 3 ARMOR study

TEL AVIV, Israel, Aug. 2, 2021 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, metabolic and inflammatory diseases announced today that the FDA agreed with its plan to use Aramchol meglumine (in lieu of Aramchol free acid) in its Phase 3 ARMOR study without the need to conduct additional nonclinical and clinical studies other than planned limited pharmacology studies relating to Aramchol meglumine.

GLMD Financial details

Company Rating
Neutral
Market Cap
1.18M
Income
-7.55M
Revenue
0
Book val./share
2.49
Cash/share
2.13
Dividend
-
Dividend %
-
Employees
4
Optionable
No
Shortable
Yes
Earnings
27 Mar 2024
P/E
-0.37
Forward P/E
-0.32
PEG
0.05
P/S
-
P/B
0.18
P/C
0.16
P/FCF
-0.18
Quick Ratio
6.74
Current Ratio
6.79
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-3.86
EPS next Y
-1.03
EPS next Q
1.58
EPS this Y
-43.12%
EPS next Y
-73.32%
EPS next 5Y
-73.83%
EPS last 5Y
6.34%
Revenue last 5Y
-100%
Revenue Q/Q
-
EPS Q/Q
-74.74%
-
-
-
-
SMA20
-18.42%
SMA50
-27.91%
SMA100
-18.42%
Inst Own
1838.53%
Inst Trans
0.86%
ROA
-43%
ROE
-59%
ROC
-0.5%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
3.81M
Shs Float
3.57M
-
-
-
-
Target Price
-
52W Range
0.26-5.63
52W High
-
52W Low
-
RSI
44.06
Rel Volume
0.09
Avg Volume
155.23K
Volume
13.96K
Perf Week
6.69%
Perf Month
-12.76%
Perf Quarter
-23.97%
Perf Half Y
-43.81%
-
-
-
-
Beta
0.884
-
-
Volatility
0.01%, 0.03%
Prev Close
3.53%
Price
0.3315
Change
2.47%

GLMD Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2022-12-31

Metric History 2018-12-312019-12-312020-12-312021-12-31 2022-12-31
2.02K2.02K2.02K2.02K2.02K
Revenue per share
1.690000
Net income per share
-8.15-13.17-19.46-19.48-11.08
Operating cash flow per share
-7.46-10.61-18.53-20.06-11.04
Free cash flow per share
-7.54-10.62-18.56-20.06-11.04
Cash per share
74.5953.6335.8721.238.22
Book value per share
72.6949.6231.1218.68.01
Tangible book value per share
72.6949.6231.1218.68.01
Share holders equity per share
72.6949.6231.1218.68.01
Interest debt per share
00.270.170.170.15
Market cap
8.26M8.14M4.41M2.98M838.09K
Enterprise value
-15.9M-7.44M-2.32M329.51K-1.13M
P/E ratio
-0.84-0.44-0.16-0.09-0.05
Price to sales ratio
4.050000
POCF ratio
-0.92-0.54-0.17-0.09-0.05
PFCF ratio
-0.91-0.54-0.17-0.09-0.05
P/B Ratio
0.090.120.10.10.06
PTB ratio
0.090.120.10.10.06
EV to sales
-7.80000
Enterprise value over EBITDA
1.540.330.08-0.010.07
EV to operating cash flow
1.760.50.09-0.010.06
EV to free cash flow
1.740.50.09-0.010.06
Earnings yield
-1.19-2.28-6.26-10.7-22.16
Free cash flow yield
-1.1-1.84-5.97-11.02-22.08
Debt to equity
00.0100.010
Debt to assets
0000.010
Net debt to EBITDA
2.340.70.220.080.12
Current ratio
33.4111.026.476.134.76
Interest coverage
0-678.06-974.52-764.67-82.1
Income quality
0.920.730.911.011.04
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
2.180000
Research and developement to revenue
4.080000
Intangibles to total assets
00000
Capex to operating cash flow
0.010000
Capex to revenue
-0.040000
Capex to depreciation
-0.23-0.34-1.13-0.26-0.11
Stock based compensation to revenue
0.870000
Graham number
115.46121.27116.7490.2944.68
ROIC
-0.12-0.29-0.65-1.05-1.36
Return on tangible assets
-0.11-0.24-0.53-0.87-1.12
Graham Net
72.3838.9729.1617.746.44
Working capital
87.7M69.5M43.8M30.18M11.63M
Tangible asset value
87.89M69.85M44.15M30.5M13.42M
Net current asset value
87.7M69.14M43.58M29.95M11.59M
Invested capital
00.0100.010
Average receivables
103K439K819.5K968.5K624.5K
Average payables
2.05M3.91M6.52M5.96M3.72M
Average inventory
-50K-13.97M-15.87M-2.37M-409K
Days sales outstanding
9.130000
Days payables outstanding
062.56K65.94K42.33K26.7K
Days of inventory on hand
0-291.35K-35.63K-8.1K1.19K
Receivables turnover
39.960000
Payables turnover
00.010.010.010.01
Inventory turnover
00-0.01-0.050.31
ROE
-0.11-0.27-0.63-1.05-1.38
Capex per share
-0.07-0.01-0.03-0.010

Quarterly Fundamentals Overview

Last date of statement is 2023-09-30 for Q3

Metric History 2022-09-302022-12-312023-03-312023-06-30 2023-09-30
2.02K2.02K2.02K2.02K2.02K
Revenue per share
00000
Net income per share
-3.2-1.68-0.99-0.95-0.24
Operating cash flow per share
-1.85-2.39-1.01-0.81-0.35
Free cash flow per share
-1.85-2.4-1.01-0.81-0.35
Cash per share
11.448.27.235.552.13
Book value per share
9.387.997.146.282.49
Tangible book value per share
9.387.997.146.282.49
Share holders equity per share
9.387.997.146.282.49
Interest debt per share
0.070.14-0.100
Market cap
522.26K840.11K717.46K5.02M3.87M
Enterprise value
-3.45M-1.13M-954.54K4.01M2.39M
P/E ratio
-0.02-0.07-0.11-0.79-0.66
Price to sales ratio
00000
POCF ratio
-0.17-0.21-0.42-3.68-1.78
PFCF ratio
-0.17-0.21-0.42-3.68-1.78
P/B Ratio
0.030.060.060.480.25
PTB ratio
0.030.060.060.480.25
EV to sales
00000
Enterprise value over EBITDA
0.640.460.48-2.16-1.64
EV to operating cash flow
1.110.280.56-2.94-1.1
EV to free cash flow
1.110.280.56-2.94-1.1
Earnings yield
-10.3-3.37-2.31-0.32-0.38
Free cash flow yield
-5.96-4.79-2.36-0.27-0.56
Debt to equity
0.010000
Debt to assets
00000
Net debt to EBITDA
0.740.810.840.541.02
Current ratio
4.074.764.583.596.79
Interest coverage
-179.33-12.8911.640-293.6
Income quality
0.581.520.930.861.48
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
00000
Research and developement to revenue
00000
Intangibles to total assets
00000
Capex to operating cash flow
00000
Capex to revenue
00000
Capex to depreciation
0-0.11000
Stock based compensation to revenue
00000
Graham number
2617.412.5911.583.63
ROIC
-0.34-0.19-0.15-0.18-0.09
Return on tangible assets
-0.26-0.17-0.11-0.12-0.08
Graham Net
8.916.435.854.121.74
Working capital
15.45M11.63M10.03M7.06M12.11M
Tangible asset value
15.75M13.42M11.99M10.55M15.55M
Net current asset value
15.36M11.59M10.03M7.06M12.11M
Invested capital
0.010000
Average receivables
882.5K637.5K346K454.5K555.5K
Average payables
3.42M3.65M2.41M2.2M1.81M
Average inventory
057K113.66K113.93K-845.73K
Days sales outstanding
00000
Days payables outstanding
025.6K25.49K21.4K0
Days of inventory on hand
01.14K1.27K1.15K0
Receivables turnover
00000
Payables turnover
00000
Inventory turnover
00.080.070.080
ROE
-0.34-0.21-0.14-0.15-0.09
Capex per share
00000

GLMD Frequently Asked Questions

What is Galmed Pharmaceuticals Ltd. stock symbol ?

Galmed Pharmaceuticals Ltd. is a IL stock and trading under the symbol GLMD

What is Galmed Pharmaceuticals Ltd. stock quote today ?

Galmed Pharmaceuticals Ltd. stock price is $0.3315 today.

Is Galmed Pharmaceuticals Ltd. stock public?

Yes, Galmed Pharmaceuticals Ltd. is a publicly traded company.

Something similar

Top by Market Cap
Top Correlated ETFs
Top Correlated Stocks
Similar Market Cap